SCHEMBL20528858

SCHEMBL20528858

COc1ccc(CNc2cc(C)nn3c(-c4ccc5c(c4)c(C)nn5C)c(C)nc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 7/20 0.54
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ACP1 P24666 3/20 0.42
TP53 P04637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMPD3 Q9NY59 1/20 0.40
GPR35 Q9HC97 1/20 0.40
PI4KA P42356 3/20 0.39
PDE2A O00408 1/20 0.39
CD38 P28907 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
NCF1 P14598 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644496 1.00 PI4KB (0.54) PI4KBMEN1KMT2AACP1TP53
SCHEMBL21628164 0.89 PI4KB (0.45) PI4KBNPC1RAB9ASMN1; SMN2PI4KA
SCHEMBL21628161 0.88 PI4KB (0.49) PI4KBPI4KA
SCHEMBL29644484 0.88 PI4KB (0.49) PI4KBPI4KA
SCHEMBL20528862 0.88 PI4KB (0.45) PI4KBSMPD3PI4KA
SCHEMBL29644505 0.88 PI4KB (0.45) PI4KBSMPD3PI4KA
SCHEMBL29644511 0.86 PI4KB (0.42) PI4KBSMPD3PI4KA
SCHEMBL20528846 0.86 PI4KB (0.42) PI4KBSMPD3PI4KA
SCHEMBL20528824 0.85 PI4KB (0.44) PI4KBPI4KA
SCHEMBL29644471 0.85 PI4KB (0.44) PI4KBPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4028131-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2023-11-22 EP claimed
EP-4028131-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2022-07-20 EP claimed
CN-110520424-B Heteroaromatic compounds for therapy 库洛维公司 2022-06-21 CN claimed
EP-3606926-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2021-05-26 EP claimed
WO-2021032611-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2021-02-25 WO claimed
EP-3606926-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2020-02-12 EP claimed
US-20200031833-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2020-01-30 US claimed
WO-2018185120-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2018-10-11 WO claimed
EP-4028131-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2023-11-22 EP disclosed
EP-4028131-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2023-11-22 EP disclosed
EP-3606926-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2021-05-26 EP disclosed
EP-3606926-B1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2021-05-26 EP disclosed
US-11001587-B2 Substituted indazoles as phosphatidylinositol kinase inhibitors CUROVIR AB (SE) 2021-05-11 US disclosed
US-11001587-B2 Substituted indazoles as phosphatidylinositol kinase inhibitors CUROVIR AB (SE) 2021-05-11 US disclosed
WO-2021032611-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2021-02-25 WO disclosed
US-20200031833-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2020-01-30 US disclosed
US-20200031833-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY CUROVIR AB (SE) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11001587-B2 Substituted indazoles as phosphatidylinositol kinase inhibitors PIKFYVE, PI4KA, PIP4K2B PI4KB 6/4885MEN1 3429/4885KMT2A 3430/4885
US-20200031833-A1 HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY BECN1, SQSTM1, TFEB PI4KB 630/4885MEN1 3067/4885KMT2A 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.